WCLC 2025 Insights: ARROS-1 Trial - Zidesamtinib in Advanced ROS1 NSCLC
WCLC 2025 Insights: ARROS-1 Trial - Zidesamtinib in Advanced ROS…
6 months ago
vumedi.com
Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025
Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesam…
8 months ago
fox4kc.com
Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARRO…
11 months ago
finanznachrichten.de
ESMO 2024 Insights: ARROS-1 Study - Zidesamtinib in Advanced ROS1 Fusion-Positive NSCLC and Other Solid Tumors
ESMO 2024 Insights: ARROS-1 Study - Zidesamtinib in Advanced …
Oct 2, 2024
vumedi.com
Findings for Zidesamtinib in Advanced ROS1 NSCLC and Other Solid Tumors | OncLive
4:02
Findings for Zidesamtinib in Advanced ROS1 NSCLC and Othe…
Oct 28, 2024
onclive.com
Zidesamtinib Clinical Trial Results for ROS1-Positive NSCLC Patients
0:09
Zidesamtinib Clinical Trial Results for ROS1-Positive NSCLC Patients
167 views11 months ago
YouTubeMCQ Pedia
Repotrectinib in Patients With ROS1 NSCLC
Repotrectinib in Patients With ROS1 NSCLC
Feb 28, 2024
vumedi.com
Nuvalent (NASDAQ: NUVL) sharpens zidesamtinib case at AA…
1 month ago
business-news-today.com
Taletrectinib for ROS1 NSCLC
3 months ago
vumedi.com
Taletrectinib in TKI-Naive Patients with ROS1+ NSCLC: Updated Dat…
2 weeks ago
vumedi.com
Targeting ROS1 in NSCLC
309 viewsNov 4, 2024
vumedi.com
WCLC 2025 Summary: Oncogene-Addicted NSCLC - Taletrectinib (R…
7 months ago
vumedi.com
ELCC 2025 Insights: Taletrectinib vs. Crizotinib in ROS1 NSCLC
26 viewsApr 21, 2025
vumedi.com
Taletrectinib Hits 46-Month PFS in TKI-Naive ROS1 NSCLC | Targete…
1 month ago
targetedonc.com
Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib…
2 months ago
marketscreener.com
2:09
Dr Liu on the TRUST-II Trial of Taletrectinib in ROS1 NSCLC | On…
Dec 6, 2024
onclive.com
Oncogene-Driven NSCLC: RET, NTRK, and ROS1
435 viewsFeb 7, 2024
vumedi.com
Phase I/II ARROS-1 Study of Zidesamtinib (NVL-520) in ROS1 F…
Sep 30, 2024
onclive.com
Molecular Tumor Board: 44-year-old male with advanced NSCLC and R…
Apr 16, 2024
labcorp.com
Nuvalent : la FDA accepte la demande de nouveau médicamen…
6 months ago
zonebourse.com
1L Options for ROS1 Rearranged NSCLC
441 viewsJan 23, 2024
vumedi.com
2:56
Dr Mok on the Efficacy of Taletrectinib in ROS1 NSCLC | On…
Oct 25, 2024
onclive.com
Nuvalent : la FDA accepte la demande de mise sur le marché d…
6 months ago
zonebourse.com
3:15
The Prevalence of ROS1 Fusions in Advanced NSCLC | OncLive
1 year ago
onclive.com
2:23
Dr Nagasaka on the Efficacy of Repotrectinib in Locally Advanced…
Jan 11, 2024
onclive.com
Emerging Treatment Options for HER2-Positive NSCLC | Targeted …
4 weeks ago
targetedonc.com
KEYNOTE-091 and IMPOWER010: adjuvant chemotherapy for NSCLC
Jul 12, 2022
vjoncology.com
2:40
Repotrectinib could be effective for treating ROS1 positive NSCLC: TR…
405 viewsOct 31, 2022
YouTubeMedical Dialogues
Nuvalent, Inc.: Nuvalent Highlights Recent Pipeline Progress, Reiterat…
6 months ago
finanznachrichten.de
8:27
Treating Rare Lung Cancer (ROS-1 Positive NSCLC) With Taletrectinib
267 views8 months ago
YouTubeCheckRare
See more videos
Static thumbnail place holder